跳至主要内容
临床试验/JPRN-UMIN000011963
JPRN-UMIN000011963已完成3 期

Double blind-randomized controlled trial for the efficacy of third line H. pylori eradication therapy between refabutin-including 10 days and 14 days regimen - Double blind-randomized controlled trial for the efficacy of third line H. pylori eradication therapy

Keio University School of Medicine0 个研究点目标入组 170 人开始时间: 2013年10月4日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
170

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients with allergy for rifamycins 2. Patients with past histry of tuberculosis or nontuberculous mycobacterial infection 3. Patients with allergy for PPIs 4. Patients with allergy for penicillin 5. Patients with severe liver injury and/or severe renal damage 6. Pregnancy or possible pregnancy 7. Patients who are taking voriconazole 8. Patients with uveitis 9. Patients who were recognized as inappropriate for entry

研究者

相似试验

Double blind-randomized controlled trial for the... | 临床试验